Comparison of Methods to Facilitate Rapid Sequence Intubation

Comparison of Mg, Ketamine, Large Dose Rocuronium, and Priming on Intubating Condition in Rapid Sequence Intubation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01479751

Enrollment

110

Registered

2011-11-24

Start date

2011-11-30

Completion date

2012-08-31

Last updated

2012-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intubating Condition

Keywords

Rocuronium, magnesium, priming, ketamine, intubation

Brief summary

In this study, methods which are known for facilitating rapid sequence intubation or accelerating rocuronium (Roc)onset are compared including magnesium (Mg), ketamine pretreatment, large dose rocuronium and priming.

Detailed description

Patients are pretreated with Mg, ketamine, or priming dose Roc. Two groups do not receive pretreatment, but are given Roc 0.6 mg/kg or 0.9 mg/kg.

Interventions

DRUGMagnesium Sulfate

Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.

DRUGKetamine

patients receive ketamine 0.5 mg/kg 2 min before Roc injection.

DRUGrocuronium

Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* age 18 - 65 years, * ASA 1 - 2, * patients scheduled for elective surgery under general anesthesia, * BMI 18.5-24.9 kg/m2 * Mallampati class I-II

Exclusion criteria

* neuromuscular disorder, * cardiac/hepatic/renal insufficiency, * pregnant. * anticipated difficult airway * medications that influence neuromuscular transmission

Design outcomes

Primary

Measure	Time frame	Description
Intubation score	participants will be followed at the time point of intubation, an expected average of 70 sec from the start of rocuronium injection.	Patients are tracheally intubated, and intubation scores(poor, good,excellent)are rated.

Secondary

Measure	Time frame	Description
Roc duration	participants will be followed when TOF count reaches two, an expected average of 40 min.	Time from the start of rocuronium injection until reappearance of two muscle twitches in TOF stimulations is measured, using ToF-Watch sx.
Roc onset	participants will be followed when TOFcount =0 within an expected average of 4 min from the start of rocuronium injection.	Time from the start of rocuronium injection until TOF count=0 using TOF-Watch sx.
Hemodynamic variables	participants will be followed at baseline, before and for 5 min after the intubation, an expected average of 8 min after the start of anesthetic induction.	Mean arterial pressure (MAP)and heart rate (HR) are measured at baseline, before intubation, and 1, 2, 3, 4, 5 min after intubation.
TOF% at intubation	participants will be followed at the time point of intubation, an expected average of 70 sec from the start of rocuronium injection.	neumeric value expressed as %, displayed on the monitor of TOF watch-Sx in TOF stimulation (ex. 5% on the display means 95% suppression of T1)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026